Closed-System CAR-T Cell Harvest with G-Rex100M and GatheRex

CAR T cell production involves collecting leukocytes, enriching for T cells, stimulating with anti-CD3/CD28 antibodies, exposing to viral vectors (retroviral, lentiviral, or non-viral transposons), and expanding cells for 10-20 days. Universal CAR T cells are generated by eliminating TCR expression to prevent alloreactivity, enabling use across any recipient. Characterization includes phenotypic analysis, purity assessment, antitumor function testing, transgene copy number, and genomic integration patterns. Release testing evaluates cell phenotype, CAR expression percentage, tumor contaminants, viral vector absence, sterility, and adventitious agents. Variations exist in starting cell purification, stimulation methods, cytokine combinations, and culture duration across different production facilities.

Achieving GMP manufacturing for mRNA therapeutics requires a multi-year pathway involving regulatory agreements, process development, and quality system establishment. Clients must define yield requirements, raw material specifications, and stability programs while ensuring GMP compatibility of materials. Quality assurance groups must align with CMOs early, as few mRNA programs have reached clinical trials. Preclinical phase involves process scale-up, raw material qualification, and master batch record development. Clinical phase locks down specifications, approves master batch records, qualifies raw materials, performs manufacturing, conducts final QC testing, and releases product per specifications. In-process and final release assays include capping assays, double-stranded RNA slot blot, poly(A) tail length analysis, residual protein and plasmid testing, UV identity, pH, purity, endotoxin, bioburden, sterility, and residual solvents.

Cellular therapy treats diseases through administration of manipulated cells (autologous, allogeneic, or xenogeneic). In Brazil, RDC 505 (ANVISA, 2001) regulates cellular therapy laboratories, with FDA and EMA standards as references. GMP principles ensure product quality, safety, purity, and potency through controlled environments, documented processes, quality control systems, validated processes, calibrated equipment, trained personnel, environmental monitoring, and traceability. CAR T cell therapy involves genetically modifying T lymphocytes to express chimeric antigen receptors (CARs) that recognize tumor antigens. The CAR contains antibody variable regions for antigen recognition and signaling domains for cell activation. This therapy is particularly effective for diffuse large B-cell lymphoma (30% of NHL cases), where 20-30% of patients are refractory to chemotherapy. The manufacturing process involves patient selection, lymphocyte collection via apheresis, cryopreservation, T cell selection and activation, expansion, genetic transduction, and quality control testing. GMP-compliant laboratories require HEPA filtration, unidirectional airflow, closed systems, and clinical-grade materials. T cell activation uses anti-CD3 antibodies on microbeads, achieving 65-75% activation. Genetic transduction uses lentiviral vectors, achieving ~35% transduction efficiency. T cell expansion uses bioreactors for 10-14 days. Cryopreservation uses DMSO with controlled rate freezing, achieving >80% recovery. Quality control includes identity testing, viability (>70%), sterility, and cytotoxicity testing. Products are only released if all quality criteria are met.

Quality Control (QC) laboratory performs testing to detect mistakes and ensure product quality. QC tests all incoming raw materials before production release, performs in-process testing during manufacturing, and tests final products against international standards. Stability testing determines expiration dates by storing products under various temperature and humidity conditions with periodic testing. QC uses high-tech equipment including HPLC for purity testing, GC for solvent residues, and UV-Vis Spectrophotometers for identification. QC sections include Wet Lab for basic tests, Instrument Lab for advanced analysis, and Microbiology Lab for sterility testing. Data integrity principles (ALCOA+) require legible, contemporaneous, original, and accurate recording with no white-out.

Quality Control testing encompasses seven teams: Sample Management (receiving, shipping, aliquoting samples), Biochem (chromatography, gel-based methods, wet chemistry), Micro (environmental monitoring, endotoxin, sterility), Stability (designing studies for cell banks, drug substance, product), Raw Material (release testing), and Lens (cell-based methods, bioassays, ELISAs, qPCR). Testing methods include SEC, IEC, CE, LC, PAGE, Western blots, ELISAs, and potency assays. The group participates in method validation and testing for new methods, working closely with manufacturing science and technology groups for tech transfer.

Cell and gene therapies require ultra-cold storage at temperatures as low as -150°C throughout the entire supply chain, from manufacturing to patient administration, because these biological materials like living cells or genetically modified viruses must remain within extremely narrow temperature and time frameworks to maintain viability; unlike standard pharmaceuticals, any deviation threatens product integrity, potentially causing wastage, lost revenue, or delayed patient access, which is why specialized logistics providers invest heavily in cryogenic infrastructure, real-time temperature monitoring, automated storage systems, and redundant security protocols to ensure these life-saving therapies reach patients safely and on time.

Cold chain logistics is a critical supply chain solution for transporting temperature-sensitive life sciences commodities, particularly advanced therapies like cell therapies that require storage at liquid nitrogen temperatures (-196°C). Unlike traditional small molecule drugs that are stable at room temperature, these living cells must be maintained at extreme cold throughout their entire journey from manufacturing to clinical administration. Effective cold chain logistics requires integrated solutions including specialized packaging, real-time monitoring systems that track temperature and location data, and precise logistics coordination to ensure products arrive within strict time windows (typically 36 hours for cell therapies) to maintain their viability and therapeutic efficacy.

This section covers the final stages of CGT manufacturing and distribution. Fill and finish equipment progresses from manual cryovials to semi-automated Crystal M1 systems during Phase 1-2, advancing to robotic lines during Phase 3 for large-scale production and reduced operator variability. Allogeneic processes require specialized equipment like PRM1 for closed-system vials or TerumoPharma for bags to consistently deliver large numbers of doses per predetermined commitments. Cryopreservation technology advances from isopropyl alcohol-based freezing using Cool Cells during research phases to controlled-rate freezers or CRFs powered by liquid nitrogen in clinical and commercial phases. Transportation and shipping technologies include dry ice containers for short-distance transport and vapor-phase liquid nitrogen shipping vessels (MBE Cryopres Cryo shipper) designed to maintain product quality for over one day in transit. Emerging cold chain service providers include Way Biopharma Services, Modal Solutions, Mnx Global, C Safe, Thermo Fisher CDMO unit, and Pantheon.

When freezing living cells for long-term storage, a specialized cryoprotective medium is essential because water inside cells would otherwise crystallize and cause cellular explosion; the process involves harvesting cells, centrifuging them, resuspending in cryoprotective solution, gradually cooling them in a foam container at -80°C overnight, then transferring to -150°C for long-term storage, with careful safety precautions including insulated gloves due to extreme cold risks, and rapid thawing in a 37°C water bath followed by rinsing with 70% ethanol before transferring to fresh growth medium.

Controlled rate freezing below -130°C is essential as measurable biological activity ceases below this temperature. Optimal post-thaw viability requires slow freezing followed by rapid thawing. Cryopreservation formulations typically include DMSO as cryoprotectant combined with storage media optimized for ionic strength, pH, and free radical scavengers. Cold chain management begins at tissue acquisition and continues until patient reintroduction. Short-term storage requires -150°C maintenance for less than half-day trips, while longer journeys up to seven days use specialized liquid nitrogen containers with continuous temperature logging. Rapid thawing using solid-state devices is preferred over water baths due to better viability outcomes and GMP compatibility.

The automation strategy progressed through distinct phases. Semi-automated suites used custom-designed machines where operators loaded products into HEPA-filtered enclosures for automated processing steps. The restrictive access barrier system separated people from products using three-axis transfer robots that remove products from incubators, process them at robotic stations, and return them. This eliminated human contact with living cell therapies, the primary contamination risk. Full automation enabled handling double lot sizes while maintaining equivalent processing rates. Grade A space optimization compressed automation to halve required clean room footprint. The automation platform strategy allowed incremental investment, starting with semi-automated suites and expanding to full automation. Critical data was routed through process control systems for real-time monitoring and archival, while non-critical data went through building control systems.

Automated closed-loop systems like the Quantum Cell Expansion System and CliniMACS Prodigy enable the production of autologous cell therapy products by eliminating open manipulations that risk microbial contamination, which becomes critical when scaling up from small laboratory batches to therapeutic quantities requiring dozens to hundreds of cell culture flasks; these systems use sealed plastic circuits with integrated modules for cell expansion, washing, magnetic separation, and electroporation, allowing complete cell therapy manufacturing from initial cell input to final product delivery under automated control.

Moving toward closed, automated, and scalable manufacturing platforms is essential for cell therapy to reach its full potential, particularly for oncology applications. The first patient dose submission in the U.S. revealed problems in the field that drove the development of more efficient systems. These platforms help manage critical raw materials for both supply chain and qualification purposes, and can help nudge regulators toward faster release processes for plasmid vectors and cell therapies. The faster development and clinical translation benefits patients, while failures are equally important to understand what doesn't work. A systematic approach to bringing quality and efficacious gene therapy to patients is of utmost importance.

The transition from semi-automatic to fully automated manufacturing involves integrating AI software with existing machinery. In semi-automatic systems, human operators are still required to monitor and control machines. When AI integration occurs, machines become fully automated, eliminating the need for human operators. This transformation requires removing infrastructure designed for human workers, such as toilets, bathrooms, breastfeeding rooms, canteens, health centers, assembly areas, and bus stops. The factory footprint can shrink dramatically, potentially to one-tenth of its original size.

Cell therapy manufacturing faces significant scaling challenges due to the complexity of cellular characteristics (anchorage-dependent vs. anchorage-independent cells), application phases, and the need for specialized bioreactor technologies; the industry is transitioning from open manual 2D unit operations to automated computer-controlled closed systems, with developments in iPSC manufacturing platforms, acoustic cell separation, and advanced analytical methods (flow cytometry, PCR, whole genome sequencing) to improve process robustness, reproducibility, and efficiency for both autologous and allogeneic applications.